Objective: To determine whether sepimostat mesilate inhibits activation of the complement pathways, and to evaluate the effectiveness of sepimostat mesilate on the development of glomerulonephritis in NZB/W F1 mice.
INTRODUCTION
The complement system is intimately involved not only in host defenses against infectious diseases but also in the pathology of many autoimmune diseases such as systemic lupus erythematosus (SLE) [1] . Activation of the complement system is triggered by immune complexes (ICs) that are either deposited or formed in situ within tissues. The kidney is a major site of immune complex deposition and complement activation, and about half of all lupus patients will develop nephritis [2] . NZB/W F1 mice spontaneously develop antibodies against autoantigens such as DNA. These antibodies form ICs and are deposited in the glomeruli. The deposited ICs trigger activation of the complement system, which causes glomerulonephritis, vasculitis, and cellular infiltration in the interstitium of the kidney [3, 4] . The clinical and immunopathological similarities to human SLE mean that the NZB/WF1 mouse model is commonly used for screening of drugs intended to treat human SLE [5] [6] [7] .
Sepimostat mesilate (6-amidino-2-naphthyl[4-(4,5-dihydro-1H-imidazol-2-yl)amino] benzoate dimethane sulfonate) is a protease inhibitor developed by Torii Pharmaceutical Co., Ltd. (Tokyo, Japan) [8] . It has inhibitory potencies against proteases including C1r, C1s, Factor D, plasmin, kallikrein, thrombin, and trypsin.
*Address correspondence to this author at the Fukushima Medical University, Department of Gastroenterology and Rheumatology, School of Medicine, 1 Hikarigaoka, Fukushima 960-1295, Japan; Tel: +81-24-547-1111; Fax: +81-24-547-2055; E-mail: chiehiro@fmu.ac.jp Furthermore, sepimostat mesilate (sepimostat) has inhibitory effects on various immunological reactions; it prevents complement-mediated hemolysis in vitro and in vivo, and protects against Forssman shock in guinea pigs [8, 9] . As described above, sepimostat prevents activation of the classical and alternative complement pathways by inhibiting C1r, C1s, and factor D. However, the effect of sepimostat on activation of the lectin pathway has not yet been studied.
In this study: 1) we determined whether sepimostat inhibits the activation of the complement lectin pathway using the Wielisa complement function kit, an enzyme immunoassay for the qualitative determination of functional classical, lectin, and alternative pathways in serum; and 2) we administered sepimostat to NZB/W F1 mice to examine whether this agent can attenuate the severity of immunocomplex-mediated glomerulonephritis by inhibiting activation of the complement system.
MATERIALS AND METHODOLOGY

Mice
Six-week-old NZB/NZW F1 mice were purchased from Japan SLC (Hamamatsu, Japan) and maintained in the animal facility of Fukushima Medical University under specific pathogen-free conditions. This study was approved by the Fukushima Medical University Animal Protocols Review Board.
Inhibition Assay of Complement Activity by Sepimostat Using the Wielisa Kit
The Wielisa kit (Wieslab AB, Lund, Sweden) is an enzyme immunoassay for the qualitative determination of functional classical, lectin, and alternative complement pathways in serum. To determine the ability of sepimostat to inhibit complement activity, the concentration of sepimostat was adjusted to 200, 100, 50, or 25 μg/ml in normal mouse serum, and the complement functional activity in each pathway was measured in the serum according to the manufacturer's instructions.
Administration of Sepimostat
Baseline was defined as when urinary protein excretion in NZB/W F1 mice exceeded 2SD when compared with Balb/c mice. This occurred when the mice were 17 weeks of age. Administration of sepimostat was started one week later, at 18 weeks of age. The mice were divided into two groups of 10 mice each. One group was the control group; mice in this group were injected intraperitoneally with 0.1 ml of 5% glucose five times per week. The treatment group received 200 μg of sepimostat intraperitoneally five times a week for 5 weeks, ending when the mice were 22 weeks of age. Blood samples were taken from the mice prior to treatment, at the end of treatment, and 2 weeks following treatment.
Measurement of Blood Urea Nitrogen (BUN)
BUN was measured by the urease/indophenol method [10, 11] . The urease reagent was prepared by adding 50 mg of jack bean urease (Wako, Osaka, Japan) to 200 mg of disodium ethylenediaminetetraacetate (EDTA-2Na). This solution was diluted to 500 ml in distilled water and adjusted to pH 7.0 with NaOH. The phenol color reagent was prepared by adding 5 g of phenol to 25 mg of Na2Fe(CN)5NO-2H2O. This solution was diluted to 500 ml in distilled water. To prepare the alkaline hypochlorite solution, 2.5 g of NaOH was dissolved in distilled water. Then, 3 ml of 10% NaOCl was added and diluted to 500 ml in distilled water. To measure BUN, 4 μl of each serum sample and standard urea solution was incubated with 200 μl of urease reagent at 37°C for 15 min. Then, 400 μl of phenol color reagent was added, followed by generous vortexing. After adding 400 μl of alkaline hypochlorite solution, sample tubes were incubated at 37°C for a further 20 min. The optical density at 560 nm was measured, and BUN levels were calculated using a standard curve.
Measurement of iC3b, C4d, and Bb in Serum
Serum levels of complement cleavage products iC3b, C4d, and Bb were measured with a MicroVue iC3b EIA kit, MicroVue C4d EIA kit, and MicroVue Bb Plus kit (Quidel, San Diego, CA) according to the manufacturer's instructions.
Urinary Protein Excretion
Mice were placed in metabolic cages for 24-h collection of urine. To prevent bacterial growth, antibiotics were added to collection vials. Urinary protein excretion was determined using the Bio-Rad protein assay kit (Hercules, CA) according to the manufacturer's instructions.
Pathology
At 44 weeks of age, the treatment and control mice were sacrificed and the kidneys were removed. They were fixed with formaldehyde, embedded in paraffin, and then sectioned before staining with hematoxylin and eosin (H&E) and periodic acid-Schiff (PAS).
Statistics
Statistical analysis was performed using the KruskalWallis test. Survival statistics were analyzed using the Kaplan-Meier method.
RESULTS
Inhibition of the Complement Activity In Vitro by Sepimostat
As shown in Fig. (1) , sepimostat at doses of 25, 50, 100, and 200 μg/ml suppressed the activity of the classical pathway, alternative pathway, and lectin pathway in normal mouse serum in a dose-dependent manner. 
BUN
To investigate the effect of sepimostat on renal disease, serum BUN levels were measured. As shown in Fig. (2) , serum BUN levels decreased in the treated group at the end of treatment (22 weeks) (243.2 ± 63.1 versus 120.9 ± 22.1 μg/dl; p<0.0001). However, by 24 weeks, serum BUN level had equalized in the two groups.
Complement Cleavage Products iC3b, C4d, and Bb
Measurement of complement cleavage products C3d, C4d, and Bb was performed at the following points: before treatment (16 weeks), at the end of treatment (22 weeks), and 2 weeks after treatment (24 weeks). As shown in Fig. (3) , significant suppression of serum C4d was observed at the end of treatment (22 weeks) in the treated group (0.244 ± 0.083 versus 0.153 ± 0.059 ng/dl; p=0.011). However, by 2 weeks after treatment, the differences were no longer significant between the control and treatment groups. There were no statistically significant differences in the serum concentrations of iC3b or Bb between the control group and the treated group at any time point (data not shown). Concentration of sepimostat mesilate g/ml Fig. (2) . Serum BUN levels in NZB/NZW F1 mice treated with sepimostat mesilate or glucose (controls). Data are expressed as the mean BUN level ± SD in each group. A significantly reduced level of BUN was observed in sera from the sepimostat-treated group at the age of 22 weeks. By 2 weeks after treatment, the differences were no longer significant between the control and treatment groups. Data were analyzed using the Kruskal-Wallis test.
Concentration of sepimostat mesilate
Fig. (3)
. Serum C4d levels in NZB/NZW F1 mice intraperitoneally injected with sepimostat mesilate or glucose (controls). Data are presented as the mean ± SD in each group. Sera were obtained at the age of 16 weeks (pretreatment) and 22 weeks (end of treatment). A significant decrease in C4d level in the sepimostattreated group was observed at 22 weeks. By 2 weeks after treatment, the differences were no longer significant between the control and treatment groups.
Urinary Protein Excretion
Mice were placed in metabolic cages for 24-h collection of urine, and we measured urine protein excretion once every 2 weeks. Fig. (4) shows the data before treatment (16 weeks), at the end of treatment (22 weeks) and 2 weeks after treatment (24 weeks). Proteinuria decreased in the treated group at the end of treatment (0.822 ± 0.116 versus 0.470 ± 0.093 mg/mouse/day; p=0.046). However, by 2 weeks after treatment, the differences were no longer significant between the control and treatment groups.
Survival of Sepimostat-Treated Mice
We did not observe prolonged survival in the treated group compared with the control group (Fig. 5) . Fig. (4) . Urinary protein excretion of NZB/NZW F1 mice. Data presented are the mean ± SD of 24 h urinary protein excretion (mg/mouse/day) of six mice in each group. Each urine samples was tested twice for protein content. At the age of 22 weeks (end of treatment), decreased urine protein excretion was observed in the treated group. By 2 weeks after treatment, the differences were no longer significant between the control and treatment groups. 
Renal Pathology
Mice surviving to 44 weeks of age were sacrificed, and the kidneys were removed for histopathological analysis. Renal findings in both the treatment and control groups included diffuse glomerular hypercellularity, wire loop lesions, mesangial expansion, and glomerular hyalinization (Fig. 6) . No improvement in pathological features was detected in the treatment group.
DISCUSSION
In this study, we investigated the ability of sepimostat to inhibit complement activation using the Wielisa complement functional test, which assesses all three complement activation pathways individually. We observed that sepimostat dose-dependently inhibited the activity of all complement pathways, suggesting that it inhibits not only C1q, C1s, and factor D as previously reported, but also other complement components that contribute to activation of the lectin pathway. If so, which component in the lectin pathway is inhibited by sepimostat? Mannose-binding lectinassociated serine protease (MASP) contributes to activation [12] [13] [14] . Considering that MASP is a member of the same family as C1r and C1s, it is possible that sepimostat may inhibit the lectin pathway by inhibiting the potency of MASP.
We also observed that the administration of sepimostat after disease onset lowered the levels of BUN, C4d, and delayed the development of proteinuria. However, once the treatment was stopped, serum levels of BUN, C4d, and proteinuria became elevated with no difference between the groups. Eventually, mortality as well as histological damage were similar between treated and untreated mice.
Although it could not be proven by immunopathological methods, the decreased serum level of C4d in the sepimostattreated group suggests that sepimostat may alleviate glomerulonephritis in the NZB/w F1 mouse by inhibiting activation of the classical pathway, the lectin pathway, or both. Clearly, sepimostat does not have the function of inhibiting the formation of ICs as well as their deposition in the kidney. Therefore, the presumed mechanism is that, by inhibiting C1r and C1s, sepimostat inhibits the activation of the classical pathway triggered by deposition of ICs in the kidney, thereby alleviating inflammation and tissue damage. It seems likely that, because of the short half-life, the effects of sepimosat cease rapidly after it is stopped, and disease activity returns.
Sepimostat inhibits proteases other than those in the complement system (C1r, C1s, Factor D), such as plasmin, kallikrein, thrombin, and trypsin. Therefore, it is possible that the reduction in proteinurea and serum BUN levels were caused not only by the inhibition of complement pathway activation, but also by the inhibition of these other serine proteases that may contribute to tissue damage in autoimmunity.
Inhibition of complement activation has been considered a potential therapeutic approach for SLE. However, the complement system appears to play a dual role in the progression of SLE; it has not only a pathogenic role in inducing local inflammation but also a beneficial role in the clearance of apoptotic cells and ICs [1] . Given that the complement system also has important physiological roles in host defense and immune homeostasis, potential risks are associated with systemic complement inhibition, particularly when prolonged treatment is required. Therefore, long-term administration of sepimostat could cause diseases (e.g., lupus-like disease, Neisseria infection) in patients with complement deficiency, due to the inhibition of the beneficial effects of complement; i.e., clearance of apoptotic cells and ICs, and host defense. Several serine protease inhibitors (i.e., nafamostat mesilate, camostat mesilate, gabexate mesilate) with similar chemical structures to sepimostat are commonly used in pancreatitis and disseminated intravascular coagulation in Japan. Although these protease inhibitors strongly inhibit activation of the complement system, there have been no reports of adverse effects of opportunistic infections resulting from immune suppression. This may relate to the short half-life of these drugs (no more than 10 minutes). Furthermore, nafamostat mesilate has been reported to ameliorate glomerulonephritis in immunocomplex disease as well as in the NZB/W F1 mouse [15] [16] [17] . Therefore, it is possible that sepimostat could be a therapeutic option for lupus nephritis patients with steroid resistance or severe immune compromise. 
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In conclusion, our study suggests that sepimostat may represent a novel treatment for immune-complex nephritis. Further long-term studies are needed to confirm the utility of this drug as a treatment for lupus nephritis.
